奈伐库单抗

化合物

奈伐库单抗INN:Nesvacumab),或译奈伐苏单抗耐斯伐库单抗,是一种实验性单克隆抗体,最初设计用于治疗癌症。它的靶标是血管生成素2英语Angiopoietin 2[1][2]截至2017年5月,该药物正处于治疗糖尿病性黄斑水肿的II期临床试验中。[3][4]该药物由再生元制药公司开发。

奈伐库单抗
单克隆抗体
种类完整抗体
目標血管生成素2英语Angiopoietin 2
臨床資料
ATC碼
  • 未分配
法律規範狀態
法律規範
  • 研究中
识别信息
CAS号1296818-77-3
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6440H9966N1722O2008S38
摩尔质量144,860.89 g·mol−1

参考资料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab页面存档备份,存于互联网档案馆), American Medical Association.
  2. ^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opinion on Investigational Drugs. October 2019, 28 (10): 861–869. PMID 31513439. doi:10.1080/13543784.2019.1667333. 
  3. ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov